Systemic therapy for hepatocellular carcinoma (HCC): From bench to bedside

Journal of the Egyptian National Cancer Institute

Volumn 25, Issue 4, 2013, Pages 165-171

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Hepatocellular carcinoma; Systemic treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LINIFANIB; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIVANTINIB; UFT;

ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CARDIOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LIVER CELL CARCINOMA; LIVER TOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

HEPATOCELLULAR CARCINOMA; SYSTEMIC TREATMENT;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 84887409830     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2013.08.002     Document Type: Review

References (47)

1. Ahmad J, Rabinovitz M. In: Brian I. Carr, editor. Hepatocellular carcinoma. Diagnosis and treatment. 2nd ed. Humana Press; 2010.
2. Venook A., Papandreou C., Furuse J., et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl. 4):5-13.
3. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(3):421-430.
4. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
5. Von Delius S., Lersch C., Mayr M., et al. Capecitabine for treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 2007, 54(80):2310-2314.
6. Hebbar M., Ernst O., Cattan S., et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 2006, 70(2):154-158. [Epub 2006 Apr 26].
7. Chao Y., Chan W.K., Birkhofer M.J., et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998, 78(1):34-39.
8. Boige V., Taïeb J., Hebbar M., et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006, 42(4):456-459. [Epub 2006 Jan 20].
9. Kim S.J., Seo H.Y., Choi J.G., et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006, 57(4):436-442. [Epub 2005 Jul 28].
10. Santoro A., Rimassa L., Borbath I., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013, 14(1):55-63. [Epub 2012 Nov 20]. 10.1016/S1470-2045(12)70490-4.
11. Pande S.B., Doval D.C., Pavithran K., et al. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: an Indian experience. Indian J Med Paediatr Oncol 2012, 33(1):42-47. 10.4103/0971-5851.96968.
12. Alberts S.R., Reid J.M., Morlan B.W., et al. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol 2012, 35(5):418-423.
13. Edeline J., Raoul J.L., Vauleon E., et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009, 15(6):713-716.
14. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5:1676-1681.
15. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97(20):1532-1538. 10.1093/jnci/dji315.
16. Abou-Alfa G.K., Morse M. Novel therapies targeted at signal transduction in liver tumors. Malignant liver tumors: current and emerging therapies 2004, 307. Jones and Bartlett, Sudbury, Canada. 2nd ed. P.A. Clavien (Ed.).
17. Govindarajan R., Siegel E., Makhoul I., et al. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol 2012, 36(3):254-257.
18. Chiorean E.G., Ramasubbaiah R., Yu M., et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist 2012, 17(1):13.
19. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657-6663.
20. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110(3):581-589.
21. Asnacios A., Fartoux L., Romano O., et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112(12):2733-2739.
22. Sanoff H.K., Bernard S., Goldberg R.M., et al. Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011, 4(3):78-83.
23. Yoshiji H., Kuriyama S., Yoshii J., et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39:1517-1524.
24. Sun W., Sohal D., Haller D.G., et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011, 117(14):3187-3192. [Epub 2011 Jan 24]. 10.1002/cncr.25889.
25. Wich C., Agaimy A., Strobel D., et al. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010, 16(28):3592-3596.
26. Hsu C.H., Yang T.S., Hsu C., et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010, 102(6):981-986. [Epub 2010 Feb 16]. 10.1038/sj.bjc.6605580.
27. Thomas M.B., Morris J.S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(6):843-850. [Epub 2009 Jan 12]. 10.1200/JCO.2008.18.3301.
28. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(12):1898-1903.
29. Alberts S.R., Fitch T.R., Kim G.P., et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment group clinical trial. Am J Clin Oncol 2012, 35(4):329-333. 10.1097/COC.0b013e3182118cdf.
30. Wörns M.A., Schuchmann M., Düber C., et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010, 79(1-2):85-92. [Epub 2010 Nov 12]. 10.1159/000320363.
31. Koeberle D., Montemurro M., Samaras P., et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a swiss group for clinical cancer research (SAKK) and swiss association for the study of the liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010, 15(3):285-292. [Epub 2010 Mar 4]. 10.1634/theoncologist.2009-0316.
32. Faivre S., Raymond E., Boucher E., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10(8):794-800. [Epub 2009 Jul 6]. 10.1016/S1470-2045(09)70171-8.
33. Park J.W., Finn R.S., Kim J., et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011, 17(7):1973-1983. [Epub 2011 Feb 24]. 10.1158/1078-0432.CCR-10-2011.
34. Llovet J., Decaens T., Raoul J., et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (hcc) who failed or were intolerant to sorafenib: results from the phase 3 brisk-ps study. J Hepatol 2012, 56(2):S549.
35. Yau T., Chan P., Wong H., et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007, 72(Suppl. 1):67-71. [Epub 2007 Dec 13].
36. Chuah B., Lim R., Boyer M., et al. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 2007, 46(2):234-238.
37. Shiah H.S., Chen C.Y., Dai C.Y., et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2013, 37(1):62-73. [Epub 2012 Nov 8]. 10.1111/apt.12132.
38. Woo H.Y., Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother 2012, 13(7):1059-1067.
39. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1-8.
40. Zhu1 A.X., Rosmorduc2 O., Evans J. Search: a phase iii, randomized double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012, 23(Suppl. 9):ixe1-ixe30. 10.1093/annonc/mds499. LBA2.
41. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
42. Cainap C., Qin S., Huang E., et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012, 30(Suppl. 34). [abstr 249].
43. Toh H.C., Chen P.-J., Carr B.I., et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013, 119:380-387.
44. Nobuoka D., Yoshikawa T., Sawada Y., et al. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother 2013, 9(1):210-212. 10.4161/hv.22473.
45. Tada F., Abe M., Hirooka M., et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012, 41(5):1601-1609. [Epub 2012 Sep 11]. 10.3892/ijo.2012.1626.
46. El Ansary M., Mogawer S., Elhamid S.A., et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. Cancer Res Clin Oncol 2013, 139(1):39-48. [Epub 2012 Aug 12]. 10.1007/s00432-012-1298-8.
47. Abdel-Rahman O., Abdel-Wahab M., Shaker M., et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013 Sep, 30(3):655. [Epub 2013 Jul 4]. 10.1007/s12032-013-0655-z.